CA3048677A1 - Formulations de nicotine a inhaler et procedes de production et d'utilisation de celles-ci - Google Patents

Formulations de nicotine a inhaler et procedes de production et d'utilisation de celles-ci Download PDF

Info

Publication number
CA3048677A1
CA3048677A1 CA3048677A CA3048677A CA3048677A1 CA 3048677 A1 CA3048677 A1 CA 3048677A1 CA 3048677 A CA3048677 A CA 3048677A CA 3048677 A CA3048677 A CA 3048677A CA 3048677 A1 CA3048677 A1 CA 3048677A1
Authority
CA
Canada
Prior art keywords
nicotine
particles
formulation
microns
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3048677A
Other languages
English (en)
Inventor
Alex Stenzler
Noe Zamel
Arthur Slutsky
Steven Ellis
Steve Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philip Morris Products SA
Original Assignee
Philip Morris Products SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/452,133 external-priority patent/US10149844B2/en
Application filed by Philip Morris Products SA filed Critical Philip Morris Products SA
Publication of CA3048677A1 publication Critical patent/CA3048677A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des formulations de poudre sèche comprenant de la nicotine, des méthodes d'utilisation de celles-ci et des procédés de production de celles-ci. Ces formulations de poudre sèche peuvent en outre comprendre des excipients, des agents thérapeutiques, et des constituants aromatiques. Ces formulations de poudre sèche peuvent être produites par des procédés par voie sèche ou des procédés par voie humide.
CA3048677A 2017-03-07 2018-03-07 Formulations de nicotine a inhaler et procedes de production et d'utilisation de celles-ci Abandoned CA3048677A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/452,133 US10149844B2 (en) 2015-09-16 2017-03-07 Inhalable nicotine formulations, and methods of making and using thereof
US15/452,133 2017-03-07
PCT/IB2018/051482 WO2018163085A1 (fr) 2017-03-07 2018-03-07 Formulations de nicotine à inhaler et procédés de production et d'utilisation de celles-ci

Publications (1)

Publication Number Publication Date
CA3048677A1 true CA3048677A1 (fr) 2018-09-13

Family

ID=61731727

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048677A Abandoned CA3048677A1 (fr) 2017-03-07 2018-03-07 Formulations de nicotine a inhaler et procedes de production et d'utilisation de celles-ci

Country Status (9)

Country Link
EP (1) EP3592352A1 (fr)
JP (2) JP7680823B2 (fr)
KR (1) KR20190126772A (fr)
CN (1) CN110300588A (fr)
CA (1) CA3048677A1 (fr)
IL (1) IL268458A (fr)
MX (1) MX2019010263A (fr)
RU (1) RU2770039C2 (fr)
WO (1) WO2018163085A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098778A (ko) * 2019-11-14 2022-07-12 필립모리스 프로덕츠 에스.에이. 개선된 담배 향이 나는 건조 분말 제형
BR112023003114A2 (pt) * 2020-09-03 2023-04-04 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade liofilizadas
US12594238B2 (en) 2020-09-03 2026-04-07 Philip Morris Products S.A. Low hygroscopicity active powder compositions
CN112841709B (zh) * 2021-01-20 2022-11-25 深圳市艾普生物科技有限公司 一种尼古丁盐的制备方法及应用
CN113880802A (zh) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法
JP2026509961A (ja) * 2022-10-27 2026-03-26 ケーティー アンド ジー コーポレイション 咳の抑制剤を含有する乾燥粉末吸入器用スティック及びそれを含む乾燥粉末吸入器
CN117322671A (zh) * 2023-11-01 2024-01-02 东莞市吉纯生物技术有限公司 一种烟碱脂质体及其制备方法与电子雾化液

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69306379T2 (de) * 1992-03-10 1997-06-12 Fisons Plc Inhalierbare arzneimittel
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002011695A2 (fr) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Poudres a inhaler de proteines en faisceau a quatre helices sechees par atomisation presentant une agregation reduite au minimum
GB2374595A (en) * 2001-04-19 2002-10-23 Warner Lambert Co Fused bicyclic or tricyclic amino acids
US8337816B2 (en) * 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US7832397B2 (en) * 2005-12-28 2010-11-16 Philip Morris Usa Inc. Aerosol powder delivery device
WO2008069972A2 (fr) * 2006-12-01 2008-06-12 Aradigm Corporation Systèmes destinés à mettre fin à l'usage du tabac
PL2739268T3 (pl) * 2011-08-01 2019-07-31 Monash University Sposób i formulacja do inhalacji
EP3129024A4 (fr) * 2014-04-08 2017-11-22 Sansa Corporation (Barbados) Inc. Formulations de nicotine et leurs procédés de préparation
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US10149844B2 (en) * 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CN105770862B (zh) * 2016-04-22 2022-01-11 北京三元基因药业股份有限公司 干扰素的干粉吸入剂
CN109310623B (zh) * 2016-06-30 2022-10-21 菲利普莫里斯生产公司 尼古丁颗粒

Also Published As

Publication number Publication date
JP2020510002A (ja) 2020-04-02
EP3592352A1 (fr) 2020-01-15
RU2770039C2 (ru) 2022-04-14
KR20190126772A (ko) 2019-11-12
JP7680823B2 (ja) 2025-05-21
WO2018163085A1 (fr) 2018-09-13
CN110300588A (zh) 2019-10-01
RU2019128062A3 (fr) 2021-05-21
JP2024150531A (ja) 2024-10-23
IL268458A (en) 2019-09-26
RU2019128062A (ru) 2021-04-07
MX2019010263A (es) 2019-10-09

Similar Documents

Publication Publication Date Title
US9585835B1 (en) Inhalable nicotine formulations and methods of making and using the same
US10660883B2 (en) Inhalable nicotine formulations, and methods of making and using thereof
JP7680823B2 (ja) 吸入可能なニコチン製剤、およびその作製および使用方法
US11707432B2 (en) System and method for controlling the harshness of nicotine-based dry powder formulations
KR102696600B1 (ko) 니코틴 제형, 및 이의 이용 및 제조방법

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220908